Eloxx Pharmaceuticals raises $50m on Nasdaq

News| Globes The company is developing a drug for treatment of cystic fibrosis. Eloxx Pharmaceuticals, which develops drugs for rare genetic diseases, announced that it has raised $50 million at $9.75 per share, 8% lower than yesterday’s market price. The company will be listed on Nasdaq following its financing round. Eloxx, which merged a year […]

U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

Multinational study expected to include clinical sites in U.S. Israel and Europe, where study has been awarded an $8.7 million grant from European Horizon 2020 Program April 25, 2018 07:00 ET | Source: Pluristem Therapeutics, Inc. HAIFA, Israel, April 25, 2018 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the […]

The Rise of #Nanomedicine

APRIL 18, 2018 | Research | NanoMagazine Medicine has been around for thousands of years, but as always, medicine is changing. Throughout the years, humans have switched from apothecary to packing active pharmaceutical ingredients (APIs) into #ingestibleDrugs, and now, #nanomedicine is developing into the medicine of the future. Here, we look at how nanomedicine is being used […]

CytoReason uses AI to personalize #drugs, opening the door to #cancer treatments

STEWART ROGERS | APRIL 16, 2018 8:30 AM   The first question most people have when talking about #artificialIntelligence is if it will help us or harm us. But in the health industry, the answer to that question is clear. Whether it is being used to identify patients at risk or interrogate #X-rays and scans to aid in diagnosis, AI promises to […]

Spotlight On Israel: Market Challenges Stunting Biopharma Growth

  23 Apr 2018 | Lucie Ellis Executive Summary Scrip investigates the big issues Israel’s #biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.   In its 70th anniversary year, Israel can rightly celebrate the boom in its high-tech sector over the last couple of decades. But while ICT companies lead the country’s […]

(Personalized medicine is approaching a major breakthrough” (Hebrew”

“הרפואה המותאמת אישית מתקרבת לפריצת דרך משמעותית” פרופ’ דיוויד סידרנסקי, חוקר סרטן נודע בארה”ב ומנהל קרן השקעות הביומד בישראל (IBF), מסביר בראיון ל”גלובס” מדוע רק עכשיו הרפואה המותאמת אישית עומדת להצדיק את ההייפ שהיה סביבה לפני עשור ● סידרנסקי מגלה גם שחברת איילה פארמה, מהחברות המובילות בפורטפוליו, מתכננת הנפקה, ומפרט את מטרות הקרן: “אנחנו מחפשים חברות […]

Healthy.io Brings Smartphone Urine Tests to U.S. Homes

The Israel-based startup partnered with the American National Kidney Foundation and Pennsylvania-based Geisinger Health System to offer its testing kits to U.S. patients Lilach Baumer | 19:26 15.04.18 The American National Kidney Foundation and Pennsylvania-based Geisinger Health System have partnered with Israel-based startup Healthy.io to enable smartphone-based urine tests at home. On Monday, the three will launch […]

Mylan buys rights to Israel-developed Multiple Sclerosis treatment

MS drug developed by Mapi Pharma requires a once-monthly injection instead of 3 times a week By TOI STAFF 11 April 2018, 12:19 am | Times New Israel Mylan already sells a generic version of Teva Pharmaceuticals’ widely-used MS treatment, Copaxone. But, if GA Depot successfully completes its Phase III clinical trials, it will be formidable competition to […]

Medtronic Buys Medical Visualization Company Visionsense for $65 Million

The medical device developer intends to integrate Israel-based Visionsense’s operations into its own activities Meir Orbach | 10:16 10.04.18 | Calcalistech Medical device maker Medtronic PLC is buying Israel-based medical visualization company Visionsense Ltd. for $65 million, two people familiar with the matter told Calcalist on condition of anonymity. Visionsense will receive an upfront payment of $40 […]

Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

  EMERGING ISRAELI BIOPHARMA FLIES FLAG FOR EX-BMS CANCER THERAPY by Phil Taylor | Apr 10, 2018 9:57am | FierceBiotech Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The new company licensed rights to BMS’s gamma secretase inhibitor BMS-906024 in December, […]